N
BCRX icon

Natixis’s BioCryst Pharmaceuticals BCRX Stock Holding History

Natixis’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,334
Closed -$17.6K – 988
2024
Q4 		$17.6K Hold
2,334
– – ﹤0.01% 940
2024
Q3 		$17.7K Hold
2,334
– – ﹤0.01% 833
2024
Q2 		$14.4K Sell
2,334
-9,350
-80% -$51.6K ﹤0.01% 830
2024
Q1 		$59.4K Buy
11,684
+9,350
+401% +$52.6K ﹤0.01% 816
2023
Q4 		$14K Hold
2,334
– – ﹤0.01% 893
2023
Q3 		$16.5K Hold
2,334
– – ﹤0.01% 878
2023
Q2 		$16.4K Sell
2,334
-593
-20% -$4.76K ﹤0.01% 909
2023
Q1 		$24.4K Sell
2,927
-1,907
-39% -$18.4K ﹤0.01% 859
2022
Q4 		$55.5K Buy
+4,834
New +$60.3K ﹤0.01% 917

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Natixis's BCRX Position: Q1 2025 in Review

Natixis sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2025, closing a stake of 2,334 shares — an estimated $17.6K sold.

Natixis first reported a position in BCRX in Q4 2022 and held it in 9 quarters. The position peaked at $59.4K in Q1 2024. 274 funds tracked by Wall St. Rank hold BCRX as of Q1 2025.

  • Natixis reported no remaining BioCryst Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 2,334 BioCryst Pharmaceuticals shares in Q1 2025, an estimated $17.6K.
  • Natixis first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Natixis's BioCryst Pharmaceuticals position peaked at $59.4K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.